Nutriband Partners with Brand Institute to Develop Global Brand Identity for Abuse-Deterrent Fentanyl Patch
Nutriband Inc. has partnered with Brand Institute to create the worldwide commercial brand identity for AVERSA FENTANYL, positioning the product to potentially become the world's first abuse-deterrent opioid patch with significant implications for addressing the opioid crisis.
Nutriband Inc. (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, has announced a strategic partnership with Brand Institute, Inc. to develop the global commercial brand name and visual identity for AVERSA FENTANYL, the company's lead product utilizing its proprietary AVERSA abuse-deterrent transdermal technology. This collaboration represents a significant step toward bringing what could become the world's first abuse-deterrent opioid patch to market.
The partnership with Brand Institute carries substantial importance given the company's dominant position in pharmaceutical branding. Brand Institute holds a 75% share of global drug name approvals and was responsible for 87% of FDA-approved names in 2024, providing Nutriband with access to extensive regulatory expertise and market positioning capabilities. The initiative will be supported by Brand Institute's regulatory subsidiary, Drug Safety Institute, which is staffed by former officials from major regulatory bodies including the FDA, EMA, Health Canada, USAN, and WHO.
AVERSA FENTANYL's development addresses a critical gap in pain management and opioid safety. The technology is specifically designed to deter misuse and reduce accidental opioid exposure, representing a potential breakthrough in combating the ongoing opioid crisis. The AVERSA technology platform can be incorporated into any transdermal patch to prevent abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, offering broader applications beyond fentanyl patches.
This partnership announcement follows the company's ongoing development efforts detailed in previous communications available through their corporate newsroom at https://ibn.fm/NTRB. The collaboration with Brand Institute signals Nutriband's commitment to establishing a strong commercial presence for AVERSA FENTANYL in global markets, leveraging Brand Institute's proven track record in navigating complex regulatory landscapes and creating successful pharmaceutical brand identities.
The timing of this partnership is particularly significant as healthcare systems worldwide continue grappling with opioid abuse challenges. The development of abuse-deterrent formulations has become a priority for regulators and healthcare providers seeking to balance effective pain management with safety concerns. Nutriband's technology represents an innovative approach to transdermal drug delivery safety, potentially setting new standards for opioid patch products.
Additional information about the company and its development programs can be found on the corporate website at https://www.nutriband.com. The partnership with Brand Institute positions Nutriband to maximize the commercial potential of AVERSA FENTANYL while addressing critical public health concerns surrounding opioid medications.